Kodiak Sciences will report topline results from its DAYBREAK Phase 3 study on September 28, giving investors and clinicians their first look at whether two molecularly distinct agents, Zenkuda (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer), can meet a non-inferiority bar against aflibercept in wet age-related macular degeneration. The unusual design, two investigational arms running in parallel inside a single registrational trial, means one readout will speak to two separate commercial bets simultaneously.
The competitive context matters. The global anti-VEGF market was valued at roughly $26 billion in 2024, and Kodiak specifically targets the $15 billion slice tied to retinal vascular diseases. That is the pool Zenkuda and KSI-501 are aimed at, and it is not an open field: the FDA approved LYTENAVA (bevacizumab-vikg) for wet AMD as recently as July 24, 2026, adding another entrant alongside established agents. Non-inferiority to aflibercept is the regulatory threshold, but differentiation on durability or dosing interval is what would actually matter commercially.
Zenkuda carries a BLA-ready profile in diabetic retinopathy and retinal vein occlusion, built on Phase 3 data already in hand, including positive results from the GLOW2 study in diabetic retinopathy. Wet AMD is the gap. KSI-501, a bispecific targeting both VEGF and IL-6 pathways, is earlier in its clinical story and has no approved indication. DAYBREAK is therefore a different kind of inflection for each molecule: a confirmatory moment for one, a proof-of-concept for the other’s mechanism in a new disease context.
Kodiak’s pipeline does not stop at DAYBREAK. A third program, KSI-101 in macular edema secondary to inflammation, is running two BLA-facing Phase 3 studies, with one analysis expected in December 2026 and a second in the second quarter of 2027. The September 28 webcast is the first of several major data windows the company expects to open before mid-2027. The number to watch on Monday is the visual acuity change from baseline relative to aflibercept, the primary endpoint that will determine whether either arm cleared the non-inferiority threshold.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
